The global oncology therapeutics landscape is witnessing an unprecedented transformation as traditional immunotherapy limitations meet revolutionary AI-powered target discovery. Cartography secures $67M in Series B funding, marking a pivotal moment where cutting-edge machine learning antigen identification converges with T-cell engager innovation for microsatellite stable colorectal cancer. This groundbreaking investment signals a new era of precision oncology excellence, where bispecific antibody platforms revolutionize how biotechs address previously untreatable cancer subtypes from South San Francisco to worldwide clinical deployment.

Pfizer Ventures Leads Colorectal Cancer T-Cell Engager Series B

Cartography’s $67M Series B funding round led by pharmaceutical giant Pfizer Ventures represents the ultimate validation of AI-powered oncology drug discovery’s transformative potential across global cancer treatment markets. With participation from new investors LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, and Lotte Holdings CVC alongside existing backers Andreessen Horowitz Bio + Health, 8VC, Wing Venture Capital, and others, this funding creates the strategic foundation for advancing lead program CBI-1214 into Phase 1 clinical trials. The Series B brings total funding to $124M following $57M Series A in 2022, demonstrating sustained institutional confidence in multi-specific antibody therapeutics targeting novel tumor antigens.

The funding round structure provides primary capital for IND filing and Phase 1 trial enrollment beginning early 2026 while validating Cartography’s exceptional deep-tech business model utilizing Atlas and Summit platforms identifying differentiated cancer targets. This capital allocation positions the company to capitalize on the massive colorectal cancer opportunity as microsatellite stable and MSI-low subtypes representing majority of patients lack effective immunotherapy options beyond traditional chemotherapy regimens.

Andreessen Horowitz Bio Backs AI Drug Discovery Platform

Founded in 2022 by visionary biotech entrepreneur Kevin Parker (CEO) and team of computational biology experts, Cartography emerged from authentic precision medicine experience recognizing the critical target discovery gap limiting immunotherapy development for common cancer subtypes. The founding team identified that while immunotherapies achieved breakthrough results for rare microsatellite instability-high colorectal cancer patients, the majority with microsatellite stable and MSI-low disease lacked targeted treatment options due to absence of validated tumor-specific antigens enabling selective immune cell engagement.

The company’s revolutionary approach combining Atlas platform analyzing every cell in healthy human body against every cancer cell with Summit technology identifying optimal target pairs created the perfect foundation for building differentiated oncology therapeutics. Cartography’s AI and machine learning-powered platform addresses the fundamental target identification challenges that previously limited biotech ability to develop T-cell engagers for common cancer subtypes through systematic antigen profiling across thousands of patient tissue samples.

South San Francisco Biotech Reaches $124M Total Funding

Cartography operates as the definitive AI-powered oncology platform enabling biotechs to launch comprehensive cancer therapeutic programs through state-of-the-art target discovery technology. The company provides integrated Atlas antigen identification, Summit target pairing capabilities, and proprietary T-cell engager engineering that power modern precision oncology while allowing partners to focus on clinical development rather than target validation complexities. Their South San Francisco headquarters positions them within Bay Area’s premier biotech ecosystem for optimal talent and infrastructure access.

The platform’s comprehensive suite transforms traditional oncology drug discovery from empirical target selection to intelligent, data-driven antigen identification systems that scale efficiently across solid tumor indications. This precision medicine infrastructure approach democratizes access to sophisticated target discovery capabilities for biotechs and pharma partners that previously required massive internal tissue profiling programs or faced impossible validation timelines identifying tumor-specific antigens enabling selective immunotherapy development.

Gilead Partnership Powers Novel Tumor Antigen Pipeline

Cartography’s funding achievement demonstrates EXTRAORDINARY institutional validation from premier pharmaceutical and venture capital investors recognizing the massive precision oncology opportunity. The company secured strategic $20M upfront payment from Gilead Sciences in 2024 for collaboration discovering therapies against novel targets for triple-negative breast cancer and lung adenocarcinoma, with Gilead responsible for advancing opted-in targets through clinical development. The Series B funding specifically targets CBI-1214 IND submission later in 2025, Phase 1 trial enrollment beginning early 2026, and expansion of preclinical pipeline including two additional solid tumor programs beyond Gilead collaboration candidates.

The participation of Pfizer Ventures partner Michael Baran joining board of directors alongside continued Andreessen Horowitz Bio + Health backing demonstrates unprecedented alignment between pharmaceutical strategic priorities and AI-powered target discovery capabilities. This convergence creates sustainable growth dynamics that support long-term adoption of Atlas and Summit platforms within oncology drug development requiring validated tumor-specific antigens for next-generation immunotherapy engineering.

LY6G6D Target Advances Into Phase 1 Clinical Trials

The Series B capital specifically targets three strategic priorities: completing IND submission for lead program CBI-1214 targeting LY6G6D antigen in microsatellite stable colorectal cancer, initiating Phase 1 clinical trial enrollment in early 2026 with patient dosing, and advancing preclinical pipeline programs identified through Atlas platform for additional solid tumor indications. As a precision oncology pioneer, Cartography plans to leverage fresh capital for unprecedented growth in serving global cancer treatment transformation requirements, positioning the company for category leadership in AI-discovered T-cell engager therapeutics. The South San Francisco location provides strategic access to world-class computational biology talent while maintaining clinical development advantages for scaling operations.

This strategic positioning represents Cartography’s evolution from AI platform company to integrated biotech with clinical-stage pipeline, leveraging proven target discovery solutions positioning CBI-1214 as potential first- and best-in-class molecule for colorectal cancer patients lacking immunotherapy options. The expansion captures emerging opportunities in precision oncology transformation as demonstrated through Gilead partnership validating Atlas and Summit capabilities identifying novel targets for aggressive cancer subtypes requiring new therapeutic modalities beyond conventional chemotherapy approaches.

---

BUSINESS MODEL OF CARTOGRAPHY

CATEGORY	DETAILED ANALYSIS
HOW CARTOGRAPHY STARTED	COMPUTATIONAL BIOLOGISTS TURN PRECISION ONCOLOGY VISIONARIES! Founded in 2022 by CEO Kevin Parker and computational biology team recognizing massive target discovery gap for common cancer subtypes! Started with eureka moment to apply AI to systematic antigen profiling without compromising tumor specificity standards. Emerged from authentic precision medicine experience combined with deep understanding of immunotherapy limitations. AUTHENTIC BIOTECH FOUNDATION transformed into revolutionary target discovery platform!
PRESENT CONDITION	$67M FUNDED AI ONCOLOGY INFRASTRUCTURE LEADER REACHING $124M TOTAL! Just secured $67M Series B led by Pfizer Ventures achieving $124M total funding with Andreessen Horowitz Bio + Health backing! Platform serves as comprehensive AI target discovery enabling colorectal cancer therapeutics through Atlas and Summit technology. $20M Gilead partnership with Phase 1 trials starting early 2026 and LY6G6D targeting! REAL PHARMA VALIDATION, REAL CLINICAL PROGRESSION, REAL PATIENT IMPACT POTENTIAL!
FUTURE OF CARTOGRAPHY & INDUSTRY	AI PRECISION ONCOLOGY REVOLUTION ACCELERATING! Company positioned for EXPLOSIVE CLINICAL DEVELOPMENT EXPANSION across colorectal and solid tumor markets under proven biotech leadership. Oncology drug discovery industry desperately needs validated tumor-specific antigens—Cartography is THE AI ENABLER! Phase 1 enrollment beginning 2026 with comprehensive pipeline expansion. Category-defining positioning creates BILLION-DOLLAR CANCER TREATMENT TRANSFORMATION opportunity!
OPPORTUNITIES FOR YOUNG ENTREPRENEURS	AI ONCOLOGY DISCOVERY IS THE NEW FRONTIER! Massive opportunities in: AI-powered target identification, T-cell engager therapeutics, Tumor antigen profiling platforms, Bispecific antibody engineering, Precision immunotherapy development, Computational cancer biology. AI oncology industry starving for discovery innovation—FIRST-MOVER ADVANTAGE across multiple therapeutic verticals!
MARKET SHARE	BAY AREA AI ONCOLOGY PLATFORM PIONEER! Atlas and Summit technologies represent unique market position in systematic antigen discovery enablement! Global cancer therapeutics market $200+ billion opportunity with precision medicine—Cartography positioned as CATEGORY CREATOR in AI-discovered T-cell engagers. Pfizer Ventures and Andreessen Horowitz backing demonstrates institutional biotech confidence with Gilead $20M partnership proving pharmaceutical validation and commercial scalability!
MOAT (COMPETITIVE ADVANTAGE)	IMPENETRABLE AI ONCOLOGY DISCOVERY FORTRESS! 1) Atlas Platform Proprietary Data—comprehensive healthy and cancer cell antigen databases impossible to replicate 2) Pfizer Ventures Strategic Investment—pharmaceutical partner validation and clinical expertise 3) Gilead $20M Partnership—big pharma collaboration validates platform capabilities 4) LY6G6D First-Mover Positioning—competing against only one Phase 1 program (QLSF Biotherapeutics) 5) South San Francisco Biotech Hub—strategic Bay Area location for talent and infrastructure! IMPOSSIBLE TO DUPLICATE ADVANTAGE COMBINATION!
HOW CARTOGRAPHY MAKES MONEY	B2B BIOTECH PLATFORM AND THERAPEUTIC REVENUE EMPIRE! Primary Revenue Streams: 1) Pharma Partnership Upfront Payments—licensing fees like $20M Gilead collaboration 2) Milestone Payment Revenue—development and regulatory achievement-based payments from partners 3) Royalty Revenue—commercial sales percentage from partnered drug approvals 4) Platform Access Licensing—Atlas and Summit technology licensing to biotechs 5) Wholly-Owned Product Revenue—future CBI-1214 commercial sales if approved for colorectal cancer. HIGH-VALUE, MILESTONE-DRIVEN BIOTECH MODEL!
KEY EVIDENCE	UNDENIABLE AI ONCOLOGY PLATFORM INFRASTRUCTURE DOMINANCE: $67M Series B funding led by Pfizer Ventures bringing total to $124M (October 2025) Pfizer partner Michael Baran joined board validates pharmaceutical strategic alignment $20M Gilead upfront partnership for triple-negative breast cancer and lung adenocarcinoma targets Phase 1 trials starting early 2026 demonstrates rapid clinical progression timeline LY6G6D targeting microsatellite stable colorectal cancer = majority patient population Andreessen Horowitz Bio + Health Series A validates venture capital biotech confidence Atlas and Summit AI platforms = differentiated computational target discovery!